Effect of Paraoxonase 1 Polymorphisms on the Response of Lipids and Lipoprotein-associated Enzymes to Treatment with Fluvastatin

This publication has 40 references indexed in Scilit:

• Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: metaanalysis of randomised controlled trials
  BMJ, 2006
• The effects of statins on high-density lipoproteins
  Current Atherosclerosis Reports, 2006
• Lipoprotein-Associated Phospholipase A2 Activity Is Associated With Risk of Coronary Heart Disease and Ischemic Stroke
  Circulation, 2005
• Lipoprotein-Associated Phospholipase A ₂ Adds to Risk Prediction of Incident Coronary Events by C-Reactive Protein in Apparently Healthy Middle-Aged Men From the General Population
  Circulation, 2004
• Lipoprotein-Associated Phospholipase A ₂ , High-Sensitivity C-Reactive Protein, and Risk for Incident Coronary Heart Disease in Middle-Aged Men and Women in the Atherosclerosis Risk in Communities (ARIC) Study
  Circulation, 2004
• Effect of hypolipidemic drugs on lipoprotein-associated platelet activating factor acetylhydrolase
  Biochemical Pharmacology, 2003
• Lipoprotein-associated phospholipase A2 (platelet-activating factor acetylhydrolase) and cardiovascular disease
  Current Opinion in Lipidology, 2003
• Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase
  Atherosclerosis Supplements, 2002
• Atorvastatin Preferentially Reduces LDL-Associated Platelet-Activating Factor Acetylhydrolase Activity in Dyslipidemias of Type IIA and Type IIB
  Arteriosclerosis, Thrombosis, and Vascular Biology, 2002
• Lipoprotein-Associated Phospholipase A₂as an Independent Predictor of Coronary Heart Disease
  New England Journal of Medicine, 2000